The development and evaluation of the efficacy of ovine-derived experimental antivenom immunoserum against Macrovipera lebetina obtusa (MLO) venom.

Here we describe the processing and development of animal-derived monovalent antibody serum against Macrovipera lebetina obtusa venom by purification and concentration of the immunoglobulins using caprylic acid. We demonstrate that this new viper venom antiserum is pre-clinically effective in neutralizing lethal toxicity and hemorrhagicity of the venom of the Armenian Levantine viper - a significant public health problem in Armenia and a wide region from south-east parts of Europe to south-west Asia. The developed product shows a high capacity to inhibit metalloproteinases and phospholipase activity of venom included in the study in comparison to current specific antivenoms, and following additional experimental approvals, it will be possible to derive the monovalent antivenom satisfying international standards, which will be much cheaper and accessible compared with the current market rivals.